Education
About Us
Working with TipRanks
Follow Us
CellSource Co., Ltd. (JP:4880)
:4880
4880 Stock Chart & Stats
¥399.00
¥37.00(4.48%)
At close: 4:00 PM EST
¥399.00
¥37.00(4.48%)
Day’s Range― - ―
52-Week Range¥360.00 - ¥850.00
Previous CloseN/A
Volume210.70K
Average Volume (3M)77.65K
Market Cap
¥7.50B
Enterprise Value¥2.84B
Total Cash (Recent Filing)¥4.71B
Total Debt (Recent Filing)¥56.72M
Price to Earnings (P/E)938.7
Beta0.76
Next Earnings
Mar 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.24%
Share Statistics
EPS (TTM)-3.81
Shares Outstanding19,847,778
10 Day Avg. Volume73,510
30 Day Avg. Volume77,646
Financial Highlights & Ratios
PEG Ratio-9.83
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.1
Revenue Forecast (FY)¥3.45B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue expansion of ~26.5% indicates growing demand or successful commercialization, strengthening the top line over multiple periods. A larger revenue base supports scale economics and funds ongoing R&D and development programs, improving long-term viability.
Conservative Balance SheetExtremely low leverage and a healthy equity ratio materially reduce financial risk and interest burden. This balance sheet conservatism provides flexibility to fund costly biotech development cycles, endure clinical or market setbacks, and pursue opportunistic investments.
Operating Cash GenerationStrong operating cash conversion versus reported net income signals core operations generate real cash, supporting ongoing operations and R&D funding. Over 2–6 months this resilience helps cover near-term obligations even if free cash flow conversion is under pressure.
Bears Say
Profit Margin CollapseA dramatic drop in net margin erodes fundamental earnings power and long-term reinvestment capacity. Such compression suggests rising costs or one-off losses that materially weaken sustainable profitability and make funding R&D or margin recovery more challenging.
ROE DeteriorationThe steep fall in return on equity indicates the company is generating almost no return on invested capital, undermining shareholder value creation. Persistently low ROE reduces ability to attract capital and signals efficiency or profitability issues that are structural if not addressed.
Weak Free Cash Flow ConversionDeclining free cash flow growth and poorer FCF-to-income conversion constrain the company's ability to self-fund development, debt repayment, or dividends. Over months this limits strategic flexibility and increases dependency on external financing for capital-intensive biotech programs.
CellSource Co., Ltd. News
4880 FAQ
What was CellSource Co., Ltd.’s price range in the past 12 months?
CellSource Co., Ltd. lowest stock price was ¥360.00 and its highest was ¥850.00 in the past 12 months.
What is CellSource Co., Ltd.’s market cap?
CellSource Co., Ltd.’s market cap is ¥7.50B.
When is CellSource Co., Ltd.’s upcoming earnings report date?
CellSource Co., Ltd.’s upcoming earnings report date is Mar 17, 2026 which is in 3 days.
How were CellSource Co., Ltd.’s earnings last quarter?
CellSource Co., Ltd. released its earnings results on Dec 11, 2025. The company reported -¥3.81 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.81.
Is CellSource Co., Ltd. overvalued?
According to Wall Street analysts CellSource Co., Ltd.’s price is currently Overvalued.
Does CellSource Co., Ltd. pay dividends?
CellSource Co., Ltd. pays a Annually dividend of ¥5 which represents an annual dividend yield of 1.24%. See more information on CellSource Co., Ltd. dividends here
What is CellSource Co., Ltd.’s EPS estimate?
CellSource Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSource Co., Ltd. have?
CellSource Co., Ltd. has 19,847,778 shares outstanding.
What happened to CellSource Co., Ltd.’s price movement after its last earnings report?
CellSource Co., Ltd. reported an EPS of -¥3.81 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CellSource Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSource Co., Ltd.
CellSource Co., Ltd. engages in the regenerative medicine-related and consumer businesses. It also offers Signalift, an anti-aging product. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―